Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
Go back to Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 27.02 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.02 | 52 Week High | $117.12 | |||
| Open | $27.02 | 52 Week Low | $46.52 | |||
| Day High | $27.02 | P/E | N/A | |||
| Day Low | $27.02 | EPS | $-1.97 | |||
| Volume | 209 | |||||
